197 related articles for article (PubMed ID: 18769688)
21. Epstein-Barr Virus in Nasopharyngeal Carcinoma of Guatemalan and Brazilian Patients.
Rumayor Piña A; Dos Santos HT; Carlos R; Altemani A; de Almeida OP
Int J Surg Pathol; 2017 Jun; 25(4):304-309. PubMed ID: 27881609
[TBL] [Abstract][Full Text] [Related]
22. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
23. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
25. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
[TBL] [Abstract][Full Text] [Related]
26. Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma.
Nakanishi Y; Wakisaka N; Kondo S; Endo K; Sugimoto H; Hatano M; Ueno T; Ishikawa K; Yoshizaki T
Cancer Metastasis Rev; 2017 Sep; 36(3):435-447. PubMed ID: 28819752
[TBL] [Abstract][Full Text] [Related]
27. [Assay of Epstein-Barr virus in nasopharyngeal tissues and serum of patients with nasopharyngeal carcinoma].
Li XM; Yang CZ; Chen PJ; Su ZL; Song Y
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Sep; 14(9):400-1. PubMed ID: 12563909
[TBL] [Abstract][Full Text] [Related]
28. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
29. STAT3 as a therapeutic target for Epstein-Barr virus (EBV): associated nasopharyngeal carcinoma.
Ho Y; Tsao SW; Zeng M; Lui VW
Cancer Lett; 2013 Apr; 330(2):141-9. PubMed ID: 23220625
[TBL] [Abstract][Full Text] [Related]
30. Nasal natural killer lymphoma associated with Epstein-Barr virus in a patient infected with human immunodeficiency virus.
Canioni D; Arnulf B; Asso-Bonnet M; Raphael M; Brousse N
Arch Pathol Lab Med; 2001 May; 125(5):660-2. PubMed ID: 11300939
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.
Ooft ML; van Ipenburg JA; Sanders ME; Kranendonk M; Hofland I; de Bree R; Koljenović S; Willems SM
J Clin Pathol; 2018 Mar; 71(3):267-274. PubMed ID: 28877959
[TBL] [Abstract][Full Text] [Related]
33. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Xue F; He X
Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
[TBL] [Abstract][Full Text] [Related]
35. Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma.
Ooft ML; van Ipenburg J; van de Loo RJM; de Jong R; Moelans CB; de Bree R; de Herdt MJ; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
Head Neck; 2018 Sep; 40(9):1986-1998. PubMed ID: 29927011
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptor 2 is highly sensitive and specific for Epstein-Barr virus-associated nasopharyngeal carcinoma.
Viswanathan K; Sadow PM
Hum Pathol; 2021 Nov; 117():88-100. PubMed ID: 34416258
[TBL] [Abstract][Full Text] [Related]
37. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.
Feng P; Ren EC; Liu D; Chan SH; Hu H
J Gen Virol; 2000 Oct; 81(Pt 10):2417-2423. PubMed ID: 10993929
[TBL] [Abstract][Full Text] [Related]
38. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation.
Gu AD; Zeng MS; Qian CN
Int J Mol Sci; 2012 Oct; 13(10):13737-47. PubMed ID: 23202978
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of Epstein-Barr virus viral load in patients with T1-T2 nasopharyngeal cancer.
Mazurek AM; Wygoda A; Rutkowski T; Olbryt M; Pietrowska M; Celejewska A; Składowski K; Widłak P
J Med Virol; 2020 Mar; 92(3):348-355. PubMed ID: 31608452
[TBL] [Abstract][Full Text] [Related]
40. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
